COST-EFFECTIVENESS OF DAPAGLIFLOZIN PLUS STANDARD TREATMENT COMPARED TO STANDARD TREATMENT FOR THE MANAGEMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN COLOMBIA

被引：0
|
作者：
Rojas, Gil Y. [1 ]
Lasalvia, P. [1 ]
Pena, Garcia A. A. [2 ]
机构：
[1] NeuroEconomix, Bogota, Colombia
[2] Hosp San Ignacio, Bogota, Colombia
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSB161
引用
收藏
页码：S92 / S92
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of add-on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes
    Abushanab, Dina
    Chbib, Salma
    Kaddoura, Rasha
    Al Hail, Moza
    Rouf, Palli Valappila Abdul
    El Kassem, Wessam
    Shah, Jassim
    Nair, Ramesh Kumar Ravindran
    Al-Badriyeh, Daoud
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 404 - 417
  • [32] Cost-Effectiveness of Dapagliflozin vs Empagliflozin for Treating Heart Failure With Reduced Ejection Fraction in the United States
    Nechi, Regina Nwamaka
    Rane, Amey
    Karaye, Rukayyah M.
    Ndikumukiza, Cyrille
    Alsahali, Saud
    Jatau, Abubakar I.
    Zoni, Cesar Rodrigo
    Alanzi, Abdullah
    Karaye, Ibraheem M.
    Yunusa, Ismaeel
    [J]. CLINICAL THERAPEUTICS, 2023, 45 (07) : 627 - 632
  • [33] Comparative Cost-Effectiveness of Sacubitril-Valsartan, Dapagliflozin, and Empagliflozin in Heart Failure With Reduced Ejection Fraction
    Parikh, Neil U.
    Dixit, Neal
    Ziaeian, Boback
    Fonarow, Gregg C.
    [J]. CIRCULATION, 2022, 146
  • [34] Cost-Effectiveness of New Quadruple Therapy Compared With Standard Treatment for Patients With Heart Failure in China
    Huang, Yun
    Zhou, Hua
    Fang, Chongbo
    Ma, Lili
    Zhang, Yuyu
    Rong, Weibo
    Liu, Xiaoli
    Ye, Honghua
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2024, 83 (01) : 86 - 92
  • [35] Cost-Effectiveness Analysis of Sacubitril/Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction in the United States
    Zueger, Patrick M.
    Kumar, Varun M.
    Harrington, Rachel L.
    Rigoni, Gianna C.
    Atwood, Alicia
    DiDomenico, Robert J.
    Touchette, Daniel R.
    [J]. PHARMACOTHERAPY, 2018, 38 (05): : 520 - 530
  • [36] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN FOR THE TREATMENT OF SYMPTOMATIC CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PORTUGAL
    Alarcao, J.
    Ascencao, R.
    Costa, J.
    Gouveia, M.
    Borges, M.
    [J]. VALUE IN HEALTH, 2018, 21 : S104 - S104
  • [37] Cost-Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States
    Reifsnider, Odette S.
    Tafazzoli, Ali
    Linden, Stephan
    Ishak, Jack
    Rakonczai, Pal
    Stargardter, Matthew
    Kuti, Effie
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (04):
  • [38] Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction
    Jiang, Juan
    Gao, Jie
    Zhang, Xiuzhen
    Li, Yuanmin
    Dang, Heqin
    Liu, Yanlin
    Chen, Wenwen
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10
  • [39] Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction
    Krittayaphong, Rungroj
    Permsuwan, Unchalee
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 322 : 183 - 190
  • [40] Cost-Effectiveness of Quadruple Therapy in Management of Heart Failure With Reduced Ejection Fraction in the United States
    Yan, Brandon W. W.
    Spahillari, Aferdita
    Pandya, Ankur
    [J]. CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2023, 16 (06): : 401 - 410
12345